EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Functional proteomic and phosphoproteomic profiling of routine FFPE CNS tumor tissue complements genomic and epigenomic characterization

Dennis Friedel, Rhaissa Ribeiro da Silva, Ivan Abdulrazak Ahmed, Beatriz Martins Wolff, Anna Neuerburg, Ramona Irsevic, Shiva Ahmadi, Ashok Kumar Jayavelu, Andreas E Kulozik, Olaf Witt, Stefan M Pfister, Sandro M Krieg und 5 weitere

Acta Neuropathologica · 2026

DOI: 10.1007/s00401-026-03091-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Neuropathologica, 2026. Verfasst von Dennis Friedel und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany. Hauptthemen laut MEDLINE: Proteomics, Central Nervous System Neoplasms, Phosphoproteins, Glioblastoma. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Else Kröner-Fresenius-Stiftung, Deutsche Forschungsgemeinschaft, Dr. Rolf M. Schwiete Stiftung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Genomic and DNA methylation-based analyses have transformed the classification of central nervous system (CNS) tumors by enabling robust molecular diagnosis and subclassification. However, these approaches primarily define tumor identity and do not directly capture the functional state of intracellular signaling networks. Proteomic and phosphoproteomic profiling provide complementary molecular layers by measuring protein abundance and site-specific phosphorylation. Recent methodological advances have made a comprehensive analysis of formalin-fixed, paraffin-embedded (FFPE) tissue increasingly feasible, raising the question of how functional proteomic information can complement established molecular diagnostics. Here, we applied an FFPE-compatible workflow for proteomic and phosphoproteomic profiling of ten comprehensively characterized glioblastomas, including five EGFR -amplified and five non-amplified tumors. Mass spectrometry generated robust proteomic and phosphoproteomic coverage across all cases. Global proteomic profiling revealed group-associated protein abundance and pathway differences, including increased EGFR abundance in EGFR -amplified tumors, while showing substantial intertumoral overlap. Protein-abundance-adjusted phosphoproteomic profiles similarly showed partial group-level separation with substantial intertumoral overlap. Differential analysis of protein-abundance-adjusted phosphoproteomic data identified 443 phosphosites based on predefined exploratory statistical criteria. Kinase-substrate enrichment further revealed coordinated EGFR- and SRC-family-associated signaling with marked variability across individual tumors. These findings demonstrate that routine FFPE tissue retains biologically coherent functional information at both the protein abundance and phosphosignaling levels that can be interpreted alongside genomic and epigenomic data. Phosphoproteomics therefore represents an orthogonal functional layer that may complement established molecular characterization of CNS tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProteomicsCentral Nervous System NeoplasmsPhosphoproteinsGlioblastomaBrain NeoplasmsHumansEpigenomicsGenomicsParaffin EmbeddingFemaleErbB Receptors

Stichwörter der Autor:innen

EGFR amplificationFFPEGlioblastomaMolecular diagnosticsPhosphoproteomics

Substanzen

PhosphoproteinsErbB Receptors

Autor:innen und Institutionen

  • Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
  • Clinical Cooperation Unit Neuropathology, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Proteomics Core Facility, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
  • Department of Pediatric Oncology, Hematology, Immunology and Pulmonology, University Hospital Heidelberg, Heidelberg, Germany.
  • Clinical Cooperation Unit Pediatric Leukemia, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.

Förderung

  • Else Kröner-Fresenius-Stiftung
  • Deutsche Forschungsgemeinschaft
  • Dr. Rolf M. Schwiete Stiftung
  • Universitätsklinikum Heidelberg

Zitieren

APA

Friedel, D., da Silva, R. R., Ahmed, I. A., Wolff, B. M., Neuerburg, A., Irsevic, R., Ahmadi, S., Jayavelu, A. K., Kulozik, A. E., Witt, O., Pfister, S. M., Krieg, S. M., Wick, W., von Deimling, A., Reuss, D. E., Sahm, F., & Sievers, P. (2026). Functional proteomic and phosphoproteomic profiling of routine FFPE CNS tumor tissue complements genomic and epigenomic characterization. Acta Neuropathologica. https://doi.org/10.1007/s00401-026-03091-6

Vancouver

Friedel D, da Silva RR, Ahmed IA, Wolff BM, Neuerburg A, Irsevic R, et al. Functional proteomic and phosphoproteomic profiling of routine FFPE CNS tumor tissue complements genomic and epigenomic characterization. Acta Neuropathologica. 2026. doi:10.1007/s00401-026-03091-6

BibTeX
@article{Friedel2026,
  author = {Friedel, Dennis and da Silva, Rhaissa Ribeiro and Ahmed, Ivan Abdulrazak and Wolff, Beatriz Martins and Neuerburg, Anna and Irsevic, Ramona and Ahmadi, Shiva and Jayavelu, Ashok Kumar and Kulozik, Andreas E and Witt, Olaf and Pfister, Stefan M and Krieg, Sandro M and Wick, Wolfgang and von Deimling, Andreas and Reuss, David E and Sahm, Felix and Sievers, Philipp},
  title = {Functional proteomic and phosphoproteomic profiling of routine FFPE CNS tumor tissue complements genomic and epigenomic characterization},
  journal = {Acta Neuropathologica},
  year = {2026},
  doi = {10.1007/s00401-026-03091-6}
}
Kostenlos starten →